NCT06242834 2026-04-01Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's LymphomaNorthwestern UniversityPhase 2 Active not recruiting32 enrolled
NCT05934838 2025-08-15A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell LymphomasWeill Medical College of Cornell UniversityPhase 1 Recruiting15 enrolled